CD274 and cancer: Understanding the mechanism of cancer cell escape from the immune system allowed for the creation of specific antibodies that, by blocking PD-1 molecules (pembrolizumab, nivolumab), PD-L1 (atezolizumab, durvalumab), and CTLA-4 (ipilimumab), restore normal activity of the immune system [13,14].